Navigation Links
Viral Enzyme Recruited in Fight Against Ear Infection

St. Jude Study Success in Using Virus Enzyme to Treat Mouse Model of Acute Otitis Media Suggests that Nasal Spray Could Be Used to Prevent Both Ear Infection and Pneumonia in People with Influenza

MEMPHIS, Tenn., March 22, 2007 /PRNewswire/ -- Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle ear infection, based on results of a study done in mice by investigators from St. Jude Children's Research Hospital and The Rockefeller University, in New York. Such a treatment would avoid the use of antibiotics, thus eliminating the problem of antibiotic resistance. A report on this study appears in the March issue of the online journal "PLoS Pathogens."

Middle ear infection, also called acute otitis media, is an inflammation of the middle ear space. About half of all children carry Streptococcus pneumoniae, the bacteria that cause acute otitis media. These bacteria migrate from the nose and throat to the middle ear after an initial influenza virus infection paves the way.

The investigators based their treatment on the ability of viruses called phages to break out of bacteria they infect by using a special enzyme to destroy the cell walls.

The success of the new treatment, which uses a phage enzyme called lysin to kill S. pneumonia, suggests that the strategy could significantly reduce the incidence of acute otitis media in the United States. More than 24 million cases are now diagnosed each year, despite the use of vaccines against S. pneumoniae.

"Lysin also appears to hold promise for preventing the secondary pneumonia caused when a person infected with S. pneumoniae is subsequently infected with the influenza virus, said Jonathan McCullers, M.D., associate member in the Infectious Diseases department at St. Jude. McCullers is first author of the "PLoS" paper.

The investigators demonstrated tha t lysin can eliminate these bacteria from the ear using mice developed at St. Jude that represented the first such model in which acute otitis media develops in a similar way that it develops the disease in children. The mice were treated by purified lysin that was prepared in the laboratory of Vincent A. Fischetti, Ph.D., a professor and co- head of the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University. He was assisted by Jutta M. Loeffler, postdoctoral associate. Fischetti is senior author of the "PLoS" paper.

"The nasal spray may eventually be used weekly during flu season to keep a person free of Streptococcus pneumoniae or after infection with the flu virus," said Fischetti. "This might truly be a case in which an ounce of prevention would be worth a pound of cure."

Other St. Jude authors of this paper include Asa Karlstrom and Amy R. Iverson (St. Jude).

This work was supported in part by the United States Public Health Service and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

CONTACT: Carrie Strehlau, St. Jude Public Relations, +1-901-495-2295,; Summer Freeman, St. Jude Public Relations,+1-901-495-3061, , or Marc Kusinitz, Ph.D.,Scientific Communications, +1-901-495-5020, carrie.strehlau@stjude.org summer.freeman@stjude.org marc.kusinitz@stjude.org

Web site: http://www.stjude.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
4. Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
5. NIEHS Researchers Identify Enzyme Critical in DNA Replication
6. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
7. Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
10. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
11. Alzheimers Drug Shows Promise in Fighting Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):